fbpx

Orgenesis Inc

ORGS

$2.11

Closing

▼-33.86%

1D

▼-57.86%

YTD

ORGS

BBG001T5TTJ9

Exchange

Sector

Market cap

$5.07M

Volume

115,890

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$5.07M

Analysts' Rating

-

Price Target (Mean)

0.00

Total Analysts

0

P/E

Operating Margin

-1727.64%

Beta

1.18

Revenue Growth

117.70%

52 week high

$10.50

52 week low

$1.95

Div. Yield

%

EPS Growth

0.00

Company Profile

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.